Haier, a business conglomerate, agreed to acquire a 20% stake in Shanghai RAAS, a producer of blood products, from Grifols, a pharmaceutical and chemical manufacturer, for $1.8bn. "SRAAS is committed to the pursuit of safety, quality, and innovation, and we share the same vision of putting people at the center of everything we do and always striving for excellence. We look forward to working together with SRAAS and Grifols further to drive integration and innovation of the plasma value chain and contribute to the sustainable development of China’s healthcare industry,” Lixia Tan, Haier Vice Chairwoman.